N
UTHR icon

Natixis’s United Therapeutics UTHR Stock Holding History

Natixis’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.9M Buy
14,571
+13,396
+1,140% +$7.54M 0.03% 344
2026
Q1 		$697K Sell
1,175
-19,474
-94% -$9.7M ﹤0.01% 754
2025
Q4 		$10.1M Buy
+20,649
New +$9.62M 0.04% 331
2025
Q3 		– Sell
-896
Closed -$257K – 1239
2025
Q2 		$257K Buy
+896
New +$268K ﹤0.01% 776
2025
Q1 		– Sell
-241
Closed -$85K – 1196
2024
Q4 		$85K Buy
+241
New +$88.6K ﹤0.01% 849
2024
Q3 		– Sell
-112
Closed -$35.7K – 1125
2024
Q2 		$35.7K Sell
112
-6,716
-98% -$1.78M ﹤0.01% 798
2024
Q1 		$1.57M Sell
6,828
-88
-1% -$19.9K 0.01% 466
2023
Q4 		$1.52M Buy
6,916
+6,211
+881% +$1.43M 0.01% 459
2023
Q3 		$159K Sell
705
-4,679
-87% -$1.08M ﹤0.01% 738
2023
Q2 		$1.19M Buy
5,384
+5,223
+3,244% +$1.16M 0.01% 512
2023
Q1 		$36.1K Sell
161
-9,039
-98% -$2.23M ﹤0.01% 849
2022
Q4 		$2.56M Sell
9,200
-45,800
-83% -$11.6M 0.01% 492
2022
Q3 		$11.5M Buy
55,000
+41,200
+299% +$9.21M 0.05% 256
2022
Q2 		$3.25M Sell
13,800
-110,500
-89% -$22.5M 0.01% 547
2022
Q1 		$22.3M Buy
124,300
+46,100
+59% +$8.78M 0.08% 238
2021
Q4 		$16.9M Buy
78,200
+3,200
+4% +$628K 0.06% 280
2021
Q3 		$13.8M Buy
+75,000
New +$14.8M 0.05% 299
2019
Q3 		– Sell
-67,758
Closed -$5.29M – 927
2019
Q2 		$5.29M Buy
67,758
+30,178
+80% +$2.82M 0.04% 313
2019
Q1 		$4.41M Buy
37,580
+18,821
+100% +$2.19M 0.03% 393
2018
Q4 		$2.04M Buy
+18,759
New +$2.18M 0.02% 420
2017
Q2 		– Sell
-2,116
Closed -$286K – 990
2017
Q1 		$286K Buy
+2,116
New +$321K ﹤0.01% 722

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Natixis's UTHR Position: Q2 2026 in Review

Natixis increased its United Therapeutics (UTHR) stake by 1,140% in Q2 2026, buying an estimated $7.54M and bringing the position to 14,571 shares worth $7.9M. The position accounts for 0.03% of the portfolio, ranked #344.

Natixis first reported a position in UTHR in Q1 2017 and has held it in 21 quarters since. The position peaked at $22.3M in Q1 2022. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Natixis held 14,571 shares of United Therapeutics worth $7.9M as of Q2 2026.
  • Natixis bought 13,396 United Therapeutics shares in Q2 2026, an estimated $7.54M.
  • United Therapeutics made up 0.03% of Natixis's portfolio in Q2 2026, its #344 holding.
  • Natixis first reported a position in United Therapeutics in Q1 2017 and has held it in 21 quarters since.
  • Natixis's United Therapeutics position peaked at $22.3M in Q1 2022.
  • 878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.